Progenics Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

29.07.15	ATRC On Watch, BIO Gets A High Five, CORI's Study Succeeds, CYTX In Style (RTTNews)
07.10.14	ACT Opens Wallet, ADHD Craters, CMRX Focuses On Ebola, REGN Gets FDA Nod (RTTNews)
30.09.14	Salix Says FDA OKs Expanded Use Of Relistor Subcutaneous Injection (RTTNews)
11.08.14	Salix Pharma Provides Update On RELISTOR SNDA - Quick Facts (RTTNews)
08.08.14	Progenics Pharma Q2 Loss Narrows (RTTNews)
31.05.14	Seattle Genetics Reports Data From Collaborator ADC Programs - Quick Facts (RTTNews)
09.05.14	Progenics Pharmaceuticals Q1 Loss Narrows - Quick Facts (RTTNews)
21.02.14	Progenics Pharma Prices $35 Mln Stock Offering (RTTNews)
09.12.13	AUXL, GILD Get Thumbs Up, COV Snaps Up GIVN, KPTI On The Move, PGNX Awaits Data (RTTNews)
25.11.13	Progenics Relaunches Registrational Trial Of Azedra To Treat Pheochromocytomas (RTTNews)
11.11.13	Progenics Q3 Loss Narrower, Beats Street (RTTNews)
13.09.10	Progenics’ Humanized Monoclonal Antibodies Significantly Improve Survival in an Animal Model of C. difficile-associated Disease (Businesswire)
08.09.10	Nuance Introduces Dragon Medical Enterprise Network Edition, Advanced Capabilities Accelerate EHR Meaningful Use (Businesswire)
08.09.10	ATP and FedEx Announce New Global Sponsorship (Businesswire)
31.08.10	Progenics Pharmaceuticals to Present Preclinical Study of Novel Monoclonal Antibodies Against C. difficile at 2010 ICAAC (Businesswire)
07.06.10	Progenics Phase 1 PSMA ADC Study Presented in New "Trials in Progress” Poster Session at ASCO Annual Meeting (Businesswire)
07.06.10	Exelixis Reports Updated Data from Multiple Clinical Trials of the PI3K Inhibitor XL147 (SAR245408) to be Presented at ASCO (Businesswire)
15.03.10	Progenics Announces Fourth Quarter and Year-End 2009 Financial Results (Businesswire)
04.02.10	Progenics Presents Novel Multiplex PI3-Kinase Inhibitors at American Association for Cancer Research Conference on Protein Translation and Cancer (Businesswire)
08.06.09	Progenics Announces Initiation of RELISTOR Clinical Trials in Japan by Ono Pharmaceutical (Businesswire)
04.02.09	Progenics Appoints Peter J. Crowley as Independent Board Member (Businesswire)
04.02.09	Progenics Appoints Peter J. Crowley as Independent Board Member (Businesswire)
10.11.08	Progenics Reports Third Quarter 2008 Financial Results and Corporate Updates (Businesswire)
04.11.08	Progenics Selects Small-Molecule Hepatitis C Drug Candidate for Clinical Development (Businesswire)
08.08.08	Progenics Pharmaceuticals Reports Second Quarter 2008 Results (Businesswire)
03.07.08	Wyeth and Progenics Receive Approval from European Commission for RELISTOR for Opioid-Induced Constipation in Advanced Illness Patients (Businesswire)
09.05.08	CORRECTING and REPLACING Progenics Pharmaceuticals Reports First Quarter 2008 Results (Businesswire)
09.05.08	Progenics Pharmaceuticals Reports First Quarter 2008 Results (Businesswire)
24.04.08	Progenics and Wyeth Announce FDA Has Approved RELISTOR (Businesswire)
01.11.07	Progenics Awarded $1.9 Million in NIH Grants for Novel Prostate Cancer Therapies (Businesswire)
15.10.07	Wyeth and Progenics to Initiate Phase 2 Trials of Oral Methylnaltrexone in Chronic-pain Setting (Businesswire)
25.07.07	Progenics Presents Additional Positive Clinical Results for HIV-Entry Inhibitor PRO 140 at International AIDS Meeting (Businesswire)
16.03.05	Progenics Pharmaceuticals Reports Fourth Quarter and Year End Results (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Geberit	608.20	0.33 %	K V
Swisscom	565.50	-0.26 %	K V
Roche Hldg G	260.20	-0.27 %	K V
Part Grp Hldg	1’093.50	-0.36 %	K V
Zurich Insur Gr	576.60	-0.93 %	K V
Swiss Life Hldg	816.20	-1.52 %	K V
Swiss Re	145.55	-1.85 %	K V
Alcon	70.56	-1.95 %	K V
Sonova Hldg	257.70	-2.05 %	K V
CieFinRichemont	155.90	-2.38 %	K V

Progenics Pharmaceuticals Aktie VALOR 552781 / ISIN US7431871067

Nachrichten zu Progenics Pharmaceuticals Inc.

Aktien Top/Flop

Meistgelesene Nachrichten